The BioPharm Brief: New Approvals, Biosimilar Competition, and Deeper Remission

Oct 15, 08:42 PM
Headliner
Share
Subscribe

FDA expands Anktiva’s bladder cancer indication, Alvotech and Advanz submit a proposed Eylea 8 mg biosimilar in Europe, and Lilly reports new remission data for Omvoh in inflammatory bowel disease.

Share
Subscribe
Next
BioPharm Brief: Gene Therapy Progress, FDA Approval, and $103M Funding
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief